

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS	4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	8	JAN 30	Saved answer limit increased
NEWS	9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	14	FEB 28	TOXCENTER reloaded with enhancements
NEWS	15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	16	MAR 01	INSPEC reloaded and enhanced
NEWS	17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	18	MAR 08	X.25 communication option no longer available after June 2006
NEWS	19	MAR 22	EMBASE is now updated on a daily basis
NEWS	20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS	21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS	22	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS	24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS	25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS EXPRESS			FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:53:15 ON 26 APR 2006

=> file medline, uspatful, dgene, embase, wpids, biosis, biotechds, fsta
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 16:53:50 ON 26 APR 2006

FILE 'USPATFULL' ENTERED AT 16:53:50 ON 26 APR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 16:53:50 ON 26 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 16:53:50 ON 26 APR 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:53:50 ON 26 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'BIOSIS' ENTERED AT 16:53:50 ON 26 APR 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 16:53:50 ON 26 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'FSTA' ENTERED AT 16:53:50 ON 26 APR 2006
COPYRIGHT (C) 2006 International Food Information Service

=> s (retro-inverted peptide)
L1 28 (RETRO-INVERTED PEPTIDE)

=> s (ZElan 144 or ZElan 145 or ZElan 146)
L2 1 (ZELAN 144 OR ZELAN 145 OR ZELAN 146)

=> d 12 ti abs ibib tot

L2 ANSWER 1 OF 1 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
TI Retro-inverted peptide used to deliver active agents across the
gastrointestinal tract to treat hypertension, diabetes, osteoporosis,
hemophilia, anemia, cancer, migraines and angina pectoris.

AN 2000-400037 [34] WPIDS

AB WO 200031123 A UPAB: 20000718

NOVELTY - A retro-inverted peptide (I) or a derivative of it, which
specifically binds to the gastro-intestinal tract receptor HPT1, hPEPT1,
D2H or hSI, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the
following:

(1) a retro-inverted peptide (II) which enhances delivery of an
active agent across the gastro-intestinal tract into the systemic, portal
or hepatic circulation;

(2) a composition, comprising (I) or (II), bound to a material
comprising an active agent used to treat a mammalian disease or disorder;

(3) a composition, comprising a chimeric protein bound to a material
comprising an active agent used to treat a mammalian disease or disorder,

the protein comprises ZElan 144, ZElan 145 or ZElan 146, or a binding portion of them fused via a covalent bond to a second protein;

(4) a composition, comprising (I) or (II) bound to a drug containing particle;

(5) a pharmaceutical composition, comprising the composition of (2) in a carrier for use in vivo in humans;

(6) an antibody, or a fragment of it, capable of immunospecifically binding (I) or (II);

(7) a composition comprising (I) or (II) coated onto, absorbed onto or covalently bonded to, the surface of a nano- or microparticle; and

(8) a nano- or microparticle formed from (I) or (II).

ACTIVITY - Hypotensive; antidiabetic; osteopathic; hemostatic; antianemic; cytostatic; antimigraine; antianginal.

MECHANISM OF ACTION - The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation.

USE - The gastrointestinal agents are used to facilitate transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation (claimed). The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, hemophilia, anemia, cancer, migraine, and angina pectoris (claimed). The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The antibodies can be used for imaging peptides after in vivo administration, to monitor treatment efficacy, to measure peptide levels in physiological samples, and in diagnostic methods.

ADVANTAGE - None given.

Dwg.0/2

ACCESSION NUMBER: 2000-400037 [34] WPIDS

DOC. NO. CPI: C2000-120829

TITLE: Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, hemophilia, anemia, cancer, migraines and angina pectoris.

DERWENT CLASS: B04

INVENTOR(S): O'MAHONY, D J; OMAHONY, D J

PATENT ASSIGNEE(S): (ELAN-N) ELAN CORP PLC

COUNTRY COUNT: 91

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000031123	A2	20000602	(200034)*	EN	36
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SL SZ TZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES					
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS					
LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL					
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2000011744	A	20000613	(200043)		
EP 1131344	A2	20010912	(200155)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT					
RO SE SI					
JP 2002530429	W	20020917	(200276)		39
EP 1131344	B1	20050803	(200551)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
DE 69926531	E	20050908	(200561)		
DE 69926531	T2	20060330	(200623)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000031123	A2	WO 1999-IE117	19991119
AU 2000011744	A	AU 2000-11744	19991119
EP 1131344	A2	EP 1999-972640	19991119
		WO 1999-IE117	19991119
JP 2002530429	W	WO 1999-IE117	19991119
		JP 2000-583950	19991119
EP 1131344	B1	EP 1999-972640	19991119
		WO 1999-IE117	19991119
DE 69926531	E	DE 1999-626531	19991119
		EP 1999-972640	19991119
		WO 1999-IE117	19991119
DE 69926531	T2	DE 1999-626531	19991119
		EP 1999-972640	19991119
		WO 1999-IE117	19991119

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000011744	A Based on	WO 2000031123
EP 1131344	A2 Based on	WO 2000031123
JP 2002530429	W Based on	WO 2000031123
EP 1131344	B1 Based on	WO 2000031123
DE 69926531	E Based on	EP 1131344
	Based on	WO 2000031123
DE 69926531	T2 Based on	EP 1131344
	Based on	WO 2000031123

PRIORITY APPLN. INFO: US 1998-109038P 19981119

=> d his

(FILE 'HOME' ENTERED AT 16:53:15 ON 26 APR 2006)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS, BIOTECHDS, FSTA'
ENTERED AT 16:53:50 ON 26 APR 2006

L1 28 S (RETRO-INVERTED PEPTIDE)
L2 1 S (ZELAN 144 OR ZELAN 145 OR ZELAN 146)

=> s l1 and (HPT1 or hPEPT1 or hSI or D2H)
L3 9 L1 AND (HPT1 OR HPEPT1 OR HSI OR D2H)

=> s l3 ti abs ibib tot

MISSING OPERATOR L3 TI

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 9 DGENE COPYRIGHT 2006 The Thomson Corp on STN

TI **Retro-inverted peptide** used to deliver
active agents across the gastrointestinal tract to treat hypertension,
diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and
angina pectoris -

AN AAB03872 peptide DGENE

AB This invention relates to retro-inverted peptides which specifically bind
to the gastro-intestinal tract receptor **HPT1**, **hPEPT1**,
D2H or **hSI**. Also included in the invention are a

retro-inverted peptide which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a **retro-inverted peptide** bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is the full length HAX42 amino acid sequence.

ACCESSION NUMBER: AAB03872 peptide DGENE
TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N) ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan021 (full length HAX42).

Applicant

L3 ANSWER 2 OF 9 DGENE COPYRIGHT 2006 The Thomson Corp on STN

TI **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AN AAB03871 peptide DGENE

AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor **HPT1**, **hPEPT1**, **D2H** or **hSI**. Also included in the invention are a **retro-inverted peptide** which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a **retro-inverted peptide** bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created.

The peptide is the full length PAX2 amino acid sequence.

ACCESSION NUMBER: AAB03871 peptide DGENE
TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan018 (full length PAX2).

Applicant

L3 ANSWER 3 OF 9 DGENE COPYRIGHT 2006 The Thomson Corp on STN

TI **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AN AAB03870 peptide DGENE
AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor **HPT1**, **hPEPT1**, **D2H** or **hSI**. Also included in the invention are a **retro-inverted peptide** which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a **retro-inverted peptide** bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is a fragment of HAX42.

ACCESSION NUMBER: AAB03870 peptide DGENE
TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan091 (HAX42 fragment).

Appl.

L3 ANSWER 4 OF 9 DGENE COPYRIGHT 2006 The Thomson Corp on STN

TI **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension,

diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AN AAB03869 peptide DGENE

AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor **HPT1**, **hPEPT1**, **D2H** or **hSI**. Also included in the invention are a **retro-inverted peptide** which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a **retro-inverted peptide** bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is a fragment of P31.

ACCESSION NUMBER: AAB03869 peptide DGENE

TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

INVENTOR: O'Mahony D J

PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.

PATENT INFO: WO 2000031123 A2 20000602 36

APPLICATION INFO: WO 1999-IE117 19991119

PRIORITY INFO: US 1998-109038 19981119

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-400037 [34]

DESCRIPTION: GIT receptor targeting peptide ZElan031 (P31 fragment).

L3 ANSWER 5 OF 9 DGENE COPYRIGHT 2006 The Thomson Corp on STN

TI **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AN AAB03868 peptide DGENE

AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor **HPT1**, **hPEPT1**, **D2H** or **hSI**. Also included in the invention are a **retro-inverted peptide** which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a **retro-inverted peptide** bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian,

especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is a fragment of PAX2.

ACCESSION NUMBER: AAB03868 peptide DGENE
TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan129 (PAX2 fragment).

L3 ANSWER 6 OF 9 DGENE COPYRIGHT 2006 The Thomson Corp on STN

TI **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AN AAB03867 peptide DGENE

AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor **HPT1**, **hPEPT1**, **D2H** or **hSI**. Also included in the invention are a **retro-inverted peptide** which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a **retro-inverted peptide** bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a retro-inversion used in the invention. The sequence is a HAX42 14 mer fragment D form retro-inversion peptide.

ACCESSION NUMBER: AAB03867 peptide DGENE
TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English

OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan146 (HAX42 fragment).

L3 ANSWER 7 OF 9 DGENE COPYRIGHT 2006 The Thomson Corp on STN

TI **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AN AAB03866 peptide DGENE

AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor **HPT1**, **hPEPT1**, **D2H** or **hSI**. Also included in the invention are a **retro-inverted peptide** which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a **retro-inverted peptide** bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a retro-inversion used in the invention. The sequence is a P31 16 mer fragment D form retro-inversion peptide.

ACCESSION NUMBER: AAB03866 peptide DGENE

TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

INVENTOR: O'Mahony D J

PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.

PATENT INFO: WO 2000031123 A2 20000602 36

APPLICATION INFO: WO 1999-IE117 19991119

PRIORITY INFO: US 1998-109038 19981119

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-400037 [34]

DESCRIPTION: GIT receptor targeting peptide ZElan145 (P31 fragment).

L3 ANSWER 8 OF 9 DGENE COPYRIGHT 2006 The Thomson Corp on STN

TI **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AN AAB03865 peptide DGENE

AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor **HPT1**, **hPEPT1**, **D2H** or **hSI**. Also included in the invention are a **retro-inverted peptide** which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a **retro-inverted peptide** bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of

active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a retro-inversion used in the invention. The sequence is a PAX2 15 mer fragment D form retro-inversion peptide.

ACCESSION NUMBER: AAB03865 peptide DGENE

TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

INVENTOR: O'Mahony D J

PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.

PATENT INFO: WO 2000031123 A2 20000602 36

APPLICATION INFO: WO 1999-IE117 19991119

PRIORITY INFO: US 1998-109038 19981119

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-400037 [34]

DESCRIPTION: GIT receptor targeting peptide ZElan144 (PAX2 fragment).

L3 ANSWER 9 OF 9 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN

TI **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, hemophilia, anemia, cancer, migraines and angina pectoris.

AN 2000-400037 [34] WPIDS

AB WO 200031123 A UPAB: 20000718

NOVELTY - A **retro-inverted peptide** (I) or a derivative of it, which specifically binds to the gastro-intestinal tract receptor **HPT1**, **hPEPT1**, **D2H** or **hSI**, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a **retro-inverted peptide** (II) which enhances delivery of an active agent across the gastro-intestinal tract into the systemic, portal or hepatic circulation;

(2) a composition, comprising (I) or (II), bound to a material comprising an active agent used to treat a mammalian disease or disorder;

(3) a composition, comprising a chimeric protein bound to a material comprising an active agent used to treat a mammalian disease or disorder, the protein comprises ZElan 144, ZElan 145 or ZElan 146, or a binding portion of them fused via a covalent bond to a second protein;

(4) a composition, comprising (I) or (II) bound to a drug containing particle;

(5) a pharmaceutical composition, comprising the composition of (2) in a carrier for use in vivo in humans;

(6) an antibody, or a fragment of it, capable of immunospecifically binding (I) or (II);

(7) a composition comprising (I) or (II) coated onto, absorbed onto or covalently bonded to, the surface of a nano- or microparticle; and

(8) a nano- or microparticle formed from (I) or (II).

ACTIVITY - Hypotensive; antidiabetic; osteopathic; hemostatic; antianemic; cytostatic; antimigraine; antianginal.

MECHANISM OF ACTION - The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of

active agents and/or enhance active agent delivery across the tract into the systemic circulation.

USE - The gastrointestinal agents are used to facilitate transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation (claimed). The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, hemophilia, anemia, cancer, migraine, and angina pectoris (claimed). The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The antibodies can be used for imaging peptides after in vivo administration, to monitor treatment efficacy, to measure peptide levels in physiological samples, and in diagnostic methods.

ADVANTAGE - None given.

Dwg.0/2

ACCESSION NUMBER: 2000-400037 [34] WPIDS

DOC. NO. CPI: C2000-120829

TITLE: **Retro-inverted peptide** used
to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, hemophilia, anemia, cancer, migraines and angina pectoris.

DERWENT CLASS: B04

INVENTOR(S): O'MAHONY, D J; OMAHONY, D J

PATENT ASSIGNEE(S): (ELAN-N) ELAN CORP PLC

COUNTRY COUNT: 91

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000031123	A2	20000602	(200034)*	EN	36
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SL SZ TZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES					
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS					
LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL					
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2000011744	A	20000613	(200043)		
EP 1131344	A2	20010912	(200155)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT					
RO SE SI					
JP 2002530429	W	20020917	(200276)		39
EP 1131344	B1	20050803	(200551)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
DE 69926531	E	20050908	(200561)		
DE 69926531	T2	20060330	(200623)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000031123	A2	WO 1999-IE117	19991119
AU 2000011744	A	AU 2000-11744	19991119
EP 1131344	A2	EP 1999-972640	19991119
		WO 1999-IE117	19991119
JP 2002530429	W	WO 1999-IE117	19991119
		JP 2000-583950	19991119
EP 1131344	B1	EP 1999-972640	19991119
		WO 1999-IE117	19991119
DE 69926531	E	DE 1999-626531	19991119
		EP 1999-972640	19991119
		WO 1999-IE117	19991119

DE 69926531 T2

DE 1999-626531

19991119

EP 1999-972640

19991119

WO 1999-IE117

19991119

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000011744	A Based on	WO 2000031123
EP 1131344	A2 Based on	WO 2000031123
JP 2002530429	W Based on	WO 2000031123
EP 1131344	B1 Based on	WO 2000031123
DE 69926531	E Based on	EP 1131344
	Based on	WO 2000031123
DE 69926531	T2 Based on	EP 1131344
	Based on	WO 2000031123

PRIORITY APPLN. INFO: US 1998-109038P

19981119

=> e O'Mahony, D/au

MISMATCHED QUOTE IN EXPAND TERM

MISMATCHED QUOTE IN EXPAND TERM

MISMATCHED QUOTE IN EXPAND TERM

MISMATCHED QUOTE IN EXPAND TERM

MISMATCHED QUOTE IN EXPAND TERM

MISMATCHED QUOTE IN EXPAND TERM

MISMATCHED QUOTE IN EXPAND TERM

MISMATCHED QUOTE IN EXPAND TERM

Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.

Refine Search

Search Results -

Terms	Documents
L2 and (hPEPT1)	3

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L3

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Wednesday, April 26, 2006 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=OR

<u>L3</u>	L2 and (hPEPT1)	3	<u>L3</u>
<u>L2</u>	L1 and (hSI)	138	<u>L2</u>
<u>L1</u>	Retro-inverted peptide	82606	<u>L1</u>

END OF SEARCH HISTORY

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Search Results - Record(s) 1 through 3 of 3 returned.

1. Document ID: US 6780846 B1

L3: Entry 1 of 3

File: USPT

Aug 24, 2004

US-PAT-NO: 6780846
DOCUMENT-IDENTIFIER: US 6780846 B1

TITLE: Membrane translocating peptide drug delivery system

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Mahony; Daniel J.	Dublin			IE
Lambkin; Imelda J.	Dublin			IE

US-CL-CURRENT: 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	NAME	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

2. Document ID: US 6703362 B1

L3: Entry 2 of 3

File: USPT

Mar 9, 2004

US-PAT-NO: 6703362
DOCUMENT-IDENTIFIER: US 6703362 B1

TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

DATE-ISSUED: March 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alvarez; Vernon L.	Morrisville	PA		
O'Mahony; Daniel J.	Dublin			IE
Lambkin; Imelda J.	Dublin			IE
Patterson; Catherine A.	Dublin			IE
Singleton; Judith	Rocky Hill	NJ		
Belinka, Jr.; Benjamin A.	Kendall Park	NJ		
Carter; John M.	Trenton	NJ		
Cagney; Gerard M.	Seattle	WA		

US-CL-CURRENT: 514/12; 424/184.1, 424/185.1, 424/400, 435/69.1, 435/69.2, 436/86, 514/2, 514/21, 530/300, 530/324, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	NAME	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

US-PAT-NO: 6699973

DOCUMENT-IDENTIFIER: US 6699973 B1

TITLE: Antibodies to peptides that target GIT receptors and related methods

DATE-ISSUED: March 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Mahony; Daniel Joseph	Blackrock			IE
Seveso; Michela	Padua			IT

US-CL-CURRENT: 530/387.9; 424/133.1, 424/135.1, 424/139.1, 424/141.1, 424/145.1,
424/152.1, 424/158.1, 530/388.1, 530/388.24, 530/389.2

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	WMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	-----	-----------	-----

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L2 and (hPEPT1)	3

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)